VivaGel® (SPL7013, or astodrimer sodium) is an innovative agent applied to a range of marketed women’s health and sexual wellness products. The safety and efficacy of VivaGel® has been successfully tested in several clinical studies. VivaGel® is a proprietary dendrimer that is antiviral and blocks bacteria.
When formulated as a mucoadhesive gel and delivered vaginally, VivaGel® has been shown to relieve the signs and symptoms of bacterial vaginosis (BV), and to reduce risk of recurrence of BV, in clinical studies.
Further, VivaGel® has been shown, in laboratory studies, to have broad-spectrum and potent antiviral activity against a wide range of viruses, including HIV, herpes simplex, hepatitis B, HPV, Zika, adenovirus, RSV and SARS-CoV-2 (the coronavirus that causes COVID-19).
Starpharma’s VivaGel® BV is a novel, breakthrough therapy for bacterial vaginosis (BV), the most common vaginal infection in the world. VivaGel® BV is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe), Betadine™ BV Gel (Asia) and Fleurstat BVgel (Australia & New Zealand) and has been licensed in more than 160 countries around the world.
Starpharma’s VivaGel® condom is the world’s first and only anti-viral condom. The condom lubricant contains VivaGel® and has been launched in Japan, Australia, Canada, and Europe.